Xbrane Biopharma AB · OMXSTO:XBRANE
Xbrane Biopharma AB — Investor Day (May 2021)
46 slides from Xbrane Biopharma AB's investor day presentation, May 17, 2021
Slide 1: Capital Markets Day May 17, 2021
STO: XBRANE Capital Markets Day May 17, 2021 Building a World-Leading Biosimilar Developer 1
Slide 2: Important information
Important information You must read the following before continuing. The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in
Slide 3: Today's agenda
Today’s agenda Topic Presenter Welcome Anette Lindqvist, CFO Introduction to Xbrane Anders Tullgren, Chairman Biosimilar market Martin Åmark, CEO XlucaneTM Martin Åmark, CEO Platform technology David Vikström, CTO, Head of R&D Facility and team Siavash Bashiri, Deputy CEO Becoming a world-leading bi
Slide 4: Today's agenda
Today’s agenda Topic Presenter Welcome Anette Lindqvist, CFO Introduction to Xbrane Anders Tullgren, Chairman Biosimilar market Martin Åmark, CEO XlucaneTM Martin Åmark, CEO Platform technology David Vikström, CTO, Head of R&D Facility and team Siavash Bashiri, Deputy CEO Becoming a world-leading bi
Slide 5: Xbrane's journey so far
Xbrane´s journey so far Establishing LEMOTM technology Advancing XlucaneTM towards market approval in 2022 Xbrane platform technology, Relative yield (g/L) (%) LEMO Stand ard 100% 80% 60% 12x 5x 3x 40% Phase III study with 583 20% patients enrolled 0% 2008 2016 2017 2018 2019 2020 2021 May 2021 Xbra
Slide 6: Xbrane 2.0 - Becoming a world leading biosimilar developer
Xbrane 2.0 - Becoming a world leading biosimilar developer Global biosimilar market (€b) 100 % 5 50 GR:2 Tap into biosimilar market - one of the fastest growing CA pharma market segments 0 2020 2026 Leverage unique platform technology, team and new lab Ambition to become a world-leading biosimilar d
Slide 7: Today's agenda
Today’s agenda Topic Presenter Welcome Anette Lindqvist, CFO Introduction to Xbrane Anders Tullgren, Chairman Biosimilar market Martin Åmark, CEO XlucaneTM Martin Åmark, CEO Platform technology David Vikström, CTO, Head of R&D Facility and team Siavash Bashiri, Deputy CEO Becoming a world-leading bi
Slide 8: Biosimilars are follow-on products to biologics post patent expiry
Biosimilars are follow-on products to biologics post patent expiry Pharmaceuticals Small molecules Biologics Aspirin: 180 Dalton Nivolumab: 150 000 Dalton • Produced via chemical synthesis • Produced via recombinant DNA technology • 60% of global market, 1-3% p.a. growth • 40% of global market, 10-1
Slide 9: Biosimilar development is difficult but faster, cheaper and with lower risk
Biosimilar development is difficult but faster, cheaper and with lower risk Novel biological drug ~10-12 years Discovery & Development Pre-clinical Phase I Phase II Phase III €1b investment Likelihood of Approval1 10% 50% Biosimilar Pre-clinical Phase I Phase III ~6-7 years €100m investment Likeliho
Slide 10: Biosimilars have taken 40% volume market share 12 months post launch
Biosimilars have taken 40% volume market share 12 months post launch EU biosimilar volume market share US biosimilar volume market share tim Filgras n o eti Ep tim ab ab ab t mum uzum ilgras p im ce b lix ma er Inf n Adali Peg-f Trast uxi Eta Ri t Average of 2-3 biosimilars per originator product an
Slide 11: High barriers of entry limits competition amongst biosimilar developers
High barriers of entry limits competition amongst biosimilar developers Xbrane has proven track- High barriers of entry record • Cell-line to • Complex development development in- and production house capabilities • Need for high yield / • Patented high low cost technologies yield / low cost platfor
Slide 12: Xbrane's main competitive advantage lies in its platform technology
Xbrane’s main competitive advantage lies in its platform technology LEMO™ – patented technology with superior yield… …leading to lower production cost Relative yield (g/L) (%) LEMOTM ”Dimmer 100% Standard ” system ”On/Off” 80% 60% 12x 5x 3x 40% 20% 0% Membrane Average of Antibody • Fixed cost per ba
Slide 13: Xbrane is one of few publicly traded companies addressing the biosimilar market
Xbrane is the one of few publicly traded companies globally, directly addressing the biosimilar market growing with 25% on annual basis Global biosimilar market growing with 25% per year Strong growth drivers Global biosimilar market (€b) 100 Patent expiry of multiple blockbuster % 1 : 25 biologics
Slide 14: Xbrane is a developer supplying biosimilars to mid/big pharma companies
Xbrane is a developer supplying biosimilars to mid/big pharma companies Biosimilar developers Mid/big pharma Key success factors for developers • Select targets with favourable supply / demand relation • Credible capability to bring product candidate to market • Timeline to allow for launch upon pat
Slide 15: Xbrane has a portfolio addressing +€11b of originator sales
Xbrane has a portfolio addressing +€11b of originator sales Originator Patent Sales Development Expected Commercialization Candidate Indication Next milestone Product Expiry 2020 Phase Launch Partner • Age-related macular degeneration • Diabetic macular 2020/22 Mid 2021 XlucaneTM €3.1b Phase III 202
Slide 16: Today's agenda
Today’s agenda Topic Presenter Welcome Anette Lindqvist, CFO Introduction to Xbrane Anders Tullgren, Chairman Biosimilar market Martin Åmark, CEO XlucaneTM Martin Åmark, CEO Platform technology David Vikström, CTO, Head of R&D Facility and team Siavash Bashiri, Deputy CEO Becoming a world-leading bi
Slide 17: Xlucane is a biosimilar to Lucentis for treatment of severe eye diseases
XlucaneTM is a biosimilar to Lucentis® for treatment of severe eye diseases Lucentis® used in treatment of severe eye diseases Global unmet medical need due to high drug cost 5 million affected eyes Europe & US, 50% treated Affected vision Normal vision Untreated Lucentis Eylea Avastin 0,6 2,5 2,5 1
Slide 18: Top-line data from Xlucane pivotal phase III trial expected in mid 2021
Top-line data from XlucaneTM pivotal phase III trial expected in mid 2021 2020 2021 2022 XlucaneTM pivotal phase III trial • 583 wAMD patients across 15 countries and 135 clinics • Parallell double blinded equivalence trial with 12 month treatment schedule Regulatory process EU and US • Change in vi
Slide 19: The retinal anti-VEGF market generates annual net-sales of +€10b
The retinal anti-VEGF market generates annual net-sales of +€10b Retinal anti-VEGF market (€b) Lucentis and Eylea similar in profile and pricing Off-label 12 Average no 6-8 6-8 6.7 6-8 9 : 10% 10.4 doses first ’16-’1 10.1 10 CAGR year: 9.4 Price per €600 €800 €800 €100* 8.2 unit EU: 8 7.6 6,8 Price
Slide 20: Bausch + Lomb and STADA addressing the €10b retinal anti-VEGF market
Bausch + Lomb and STADA addressing the €10b retinal anti-VEGF market €6b retinal anti-VEGF market €4b retinal anti-VEGF market • €3.6b eye product and pharma specialist • €2.6b generic and biosimilar specialist • Existing ophthalmic sales force with strong • Dedicated cross European biosimilar team
Slide 21: Xlucane expected to generate net-income of +€100m three years after launch
XlucaneTM expected to generate net-income of +€100m three years after launch x 25% market share Lucentis® annual sales €3.1b1 x 50% price discount Implied annual sales €800m – Costs & profit splits XlucaneTM annual sales €400m XlucaneTM annual net-income +€100m 21 Note (1): Annual sales for Lucentis
Slide 22: Xlucane - significant potential upside beyond +€100m net-income target
XlucaneTM – significant potential upside beyond +€100m net-income target Potential upside +€100m Annual Annual net- net- Taking market Market expansion income share from Taking market share through more patients income from off-label Avastin® target Eylea® and doses per patient target Adressable Sal
Slide 23: Today's agenda
Today’s agenda Topic Presenter Welcome Anette Lindqvist, CFO Introduction to Xbrane Anders Tullgren, Chairman Biosimilar market Martin Åmark, CEO XlucaneTM Martin Åmark, CEO Platform technology David Vikström, CTO, Head of R&D Facility and team Siavash Bashiri, Deputy CEO Becoming a world-leading bi
Slide 24: Xbrane's platform technology is a toolbox of proprietary technologies
Xbranes platform technology is a “toolbox” of proprietary technologies and know-how that results in high yield / low cost biosimilars Gene construct Host cell Process Target Protein/Biosimilar TOR MO PRO GENE PLASMID MARK ER • Expression control • Proprietary engineered strain library in • USP - Opt
Slide 25: Xbrane's proprietary LEMO technology enables high-yield & low unit cost
Xbrane’s proprietary LEMO™ technology enables high-yield & low unit cost LEMO™ allows regulation of production intensity… …leading to higher yield and lower cost ARD R ND Relative yield (g/L) (%) STA MOTO STD. SYSTEM PRO LEMO Standard GENE PLASMID 100% 80% ON/OFF MARK ER switch 60% 12x 5x 3x 40% Gen
Slide 26: Case example: 4-5x yield advantage for Xcimzane
Case example: 4-5x yield advantage for XcimzaneTM Example of Key technologies from “toolbox” used 4-5x yield advantage Gene construct • Rhamex • Signal sequences Relative yield (g/L) (%) • Translation Initiation Region Xbrane (Xcimzane*) Originator (Cimzia*) 100% Host cell 80% • Strain engineering (
Slide 27: Xbrane is expanding its platform to mammalian cells to develop more targets
Xbrane is expanding its platform to mammalian cells to develop more targets Yield (g/l) 2023 Proprietary 3rd target mammalian strain 2022: Xbrane proprietary expression vector Proprietary strain TIS Construct design 2nd target Signal sequences Vector integration 2021: Significant yield In-house scal
Slide 28: Today's agenda
Today’s agenda Topic Presenter Welcome Anette Lindqvist, CFO Introduction to Xbrane Anders Tullgren, Chairman Biosimilar market Martin Åmark, CEO XlucaneTM Martin Åmark, CEO Platform technology David Vikström, CTO, Head of R&D Facility and team Siavash Bashiri, Deputy CEO Becoming a world-leading bi
Slide 29: Xbrane's new facilities entail process development up to 200L scale
Xbrane´s new facilities entails process development of CHO and E.coli expressed proteins up to 200L scale and wide range of bioanalytics State-of-the-art pilot scale development lab Capabilities in place to develop E. coli and CHO established at Campus Solna (2000 m2) derived biosimilar candidates t
Slide 30: Virtual tour of the premises
Virtual tour of the premises 30
Slide 31: Diverse, qualified and motivated team
Diverse, qualified and motivated team Rapidly growing R&D team in Sweden Diverse, qualified and motivated team +27.5% Xbrane team Most common background 60 Equality International Experience Motivation 12 ~49/51 ~53% 43.8 42 Women and men International origin Median age eNPS score 40 6 in staff 38% P
Slide 32: Today's agenda
Today’s agenda Topic Presenter Welcome Anette Lindqvist, CFO Introduction to Xbrane Anders Tullgren, Chairman Biosimilar market Martin Åmark, CEO XlucaneTM Martin Åmark, CEO Platform technology David Vikström, CTO, Head of R&D Facility and team Siavash Bashiri, Deputy CEO Becoming a world-leading bi
Slide 33: Xbrane has a clear purpose
Xbrane has a clear purpose Biologics provide However with limited Leading to an unsustainable revolutionary treatments accessibility situation • Severe eye disease (anti-VEGFs) • ”…less than two percent of Americans • “…the highest attainable standard of • Immuno-oncology (PD1s) use biologics, but t
Slide 34: Xbrane has established a powerful R&D engine
Xbrane has established a powerful R&D engine Platform with LEMOTM as core Diverse, qualified and motivated State of the art facility technology team Relative yield (g/L) (%) Xbrane team LEMO Stand ard 60 100% 80% 40 60% 40% 20 20% 0% + + 0 Membrane Average of Antib ody protein 16 different fragment
Slide 35: Xbrane has a portfolio addressing +€11b of originator sales
Xbrane has a portfolio addressing +€11b of originator sales Originator Patent Sales Development Expected Commercialization Candidate Indication Next milestone Product Expiry 2020 Phase Launch Partner • Age-related macular degeneration • Diabetic macular 2020/22 Mid 2021 XlucaneTM €3.1b Phase III 202
Slide 36: Xcimzane is the only publicly known biosimilar candidate to Cimzia
XcimzaneTM is the only publicly know biosimilar candidate to Cimzia® – a Rheumatoid Arthritis and Psoriasis drug XcimzaneTM is the only biosimilar candidate to Cimzia® is a niche €1.8b TNF inhibitor Cimzia under development globally Rheumatoid Arthritis (RA) Psoriasis Relative yield (g/L) (%) Xbrane
Slide 37: Xdivane is a frontrunner biosimilar candidate to Opdivo
XdivaneTM is a frontrunner biosimilar candidate to leading €6b immuno- oncology product Opdivo® Opdivo® is a leading €6b immuno-oncology XdivaneTM is a frontrunner biosimilar candidate to product Opdivo® • High yield /low cost based on platform technology • On path to market approval at time of pate
Slide 38: Xbrane has a stringent and proven target selection process
Xbrane has a stringent and proven target selection process Biological blockbusters World-leading high potential low risk portfolio Increase accessibility of 1 biologics Realize meaningful 2 savings Patent LOE in +expiry 7 yearsin +7 years +2028 patent expiry biological blockbusters Risk reduced and
Slide 39: Xlucane provides blueprint for upcoming development programs
XlucaneTM provides blueprint for upcoming development programs Approx. yearly development €5m €15*m €5m expense: *assuming 50% co-funding EU/US Pre-clinical Phase I and III reg. 2-3 years 3 years 1 year Approval Commercial scale manufacturing 95% Partnering with 50/50 78% co-funding of continued dev
Slide 40: Ambition to become cash-flow positive late 2023/early 2024
Xbrane´s ambition to become cash-flow positive late 2023/early 2024 while building broader portfolio …can be achieved with XlucaneTM as blueprint for coming Xbrane’s ambition… development programs 2021 2022 2023 2024 2025 • XlucaneTM EU / US approval 2022 Candidate and net-income of +€100m 2025 Xluc
Slide 41: Multiple important milestones to 2023
Multiple important milestones to 2023 Complementary deals in China, Japan and LATAM EU reg US reg Xlucane™ filing filing Top-line phase III data Launch 2021-2023: Initiating development of 3 new biosimilar candidates H1 2021 H2 2021 H1 2022 H2 2022 2023 Xcimzane™ Xcimzane™ Xdivane™ Deal with Demonst
Slide 42: Xbrane 2.0 - Becoming a world leading biosimilar developer
Xbrane 2.0 - Becoming a world leading biosimilar developer Global biosimilar market (€b) 100 % 5 50 GR:2 Tap into biosimilar market - one of the fastest growing CA pharma market segments 0 2020 2026 Leverage unique platform technology, team and new lab Ambition to become a world-leading biosimilar d
Slide 43: STO: XBRANE
Ww 2 <x a =) x< 2 7,)
Slide 44: Other Income and Company Expenses (G&A and R&D)
Other Income and Company Expenses (G&A and R&D) -16.7% -3.2% • Total income (revenue and other operational income) of SEK 4.1m (4.9). • R&D expenses decreased slightly compared to the first quarter last year. This is considered as normal fluctuations between comparing periods. • Revenue mainly gaine
Slide 45: Net Results on same level as Q1 2020
Net Results on same level as Q1 2020. Shareholders’ Equity has increased due to new share issue during 2020. * +49.4% +1.1% *This period has been recalculated due to restatement, see Appendix 1 for the effects. • Net result slightly increased. Normal fluctuations between periods. • Share issue in Q2
Slide 46: Positive Operating Cashflow in Q1
Positive Operating Cashflow in Q1 +109.5% +183.2% • Positive operating cashflow due to large re-invoicing to STADA with • Large increase in CCE compared to prior year due to new share issue payment in January 2021, according to R&D co-development agreement during 2020. (split 50/50). 46